Clinical trials in Bordeaux – page 13

1 156 clinical trials in Bordeaux, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Bordeaux at a glance

1 156

clinical trials

Research sites2

Quick filters

1 156 trials in Bordeaux

Open in trial search

Non-small cell lung cancer+1

Recruiting

Study of trastuzumab deruxtecan with pembrolizumab versus platinum chemotherapy with pembrolizumab for patients with untreated HER2-positive non-small cell lung cancer

Registered drugNo placebo

Study of trastuzumab deruxtecan with pembrolizumab versus platinum chemotherapy with pembrolizumab for patients with untreated HER2-positive non-small cell lung cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Ischaemic stroke

Recruiting

Study of alteplase and tenecteplase for intravenous thrombolysis in patients with ischemic stroke who are taking direct oral anticoagulants

Registered drugNo placebo

Study of alteplase and tenecteplase for intravenous thrombolysis in patients with ischemic stroke who are taking direct oral anticoagulants

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Alteplase
Sponsor:Insel Gruppe AG

Contact Research Centre

Pulmonary tuberculosis

Recruiting

Study of bedaquiline, pretomanid, linezolid and moxifloxacin combination treatment for patients with multidrug-resistant tuberculosis in France

Registered drugNo placebo

Study of bedaquiline, pretomanid, linezolid and moxifloxacin combination treatment for patients with multidrug-resistant tuberculosis in France

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bedaquiline
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

B-cell lymphoma recurrent+1

Recruiting

Study of drug combination therapy in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma using odronextamab, loncastuximab tesirine and rituximab

Registered drugNo placebo

Study of drug combination therapy in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma using odronextamab, loncastuximab tesirine and rituximab

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years
Substances:Carboplatin
Sponsor:The University Of Birmingham

Contact Research Centre

Brain neoplasm

Recruiting

Study of Tarlatamab and Temozolomide combination treatment in adolescents and adults with high grade brain tumors

Registered drugNo placebo

Study of Tarlatamab and Temozolomide combination treatment in adolescents and adults with high grade brain tumors

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Tarlatamab
Sponsor:Centre Leon Berard

Contact Research Centre

Relapsing multiple sclerosis

Recruiting

Study comparing remibrutinib and ocrelizumab in patients with relapsing multiple sclerosis who switch from ocrelizumab treatment

Registered drugNo placebo

Study comparing remibrutinib and ocrelizumab in patients with relapsing multiple sclerosis who switch from ocrelizumab treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Ocrelizumab
Sponsor:Novartis Pharma AG

Contact Research Centre

Adenocarcinoma pancreas+2

Recruiting

Study of 177Lu-FAP-2286 alone and with drug combinations for patients with advanced solid tumors including non-small cell lung cancer, breast cancer, and pancreatic cancer

Registered drugNo placebo

Study of 177Lu-FAP-2286 alone and with drug combinations for patients with advanced solid tumors including non-small cell lung cancer, breast cancer, and pancreatic cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Novartis Pharma AG

Contact Research Centre

Breast cancer

Recruiting

Evaluating Elacestrant alone or with leuprorelin in premenopausal women with early-stage hormone receptor positive breast cancer before surgery

Registered drugNo placebo

Evaluating Elacestrant alone or with leuprorelin in premenopausal women with early-stage hormone receptor positive breast cancer before surgery

Registered drugNo placebo

France

Participants:18–64 years
Substances:Leuprorelin Acetate
Sponsor:Institut Gustave Roussy

Contact Research Centre

Squamous cell carcinoma of head and neck

Recruiting

Study of ficerafusp alfa and pembrolizumab as first treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer

Registered drug

Study of ficerafusp alfa and pembrolizumab as first treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Bicara Therapeutics Inc.

Contact Research Centre

IgA nephropathy

Recruiting

Study of felzartamab compared to placebo in adults with IgA nephropathy

Registered drug

Study of felzartamab compared to placebo in adults with IgA nephropathy

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Codeine Phosphate
Sponsor:Biogen Idec Research Limited

Contact Research Centre

Vitiligo

Recruiting

Study of Ritlecitinib Combined with Narrow Band UVB Light Therapy Compared to Ritlecitinib Alone in Adults with Vitiligo

Registered drugNo placebo

Study of Ritlecitinib Combined with Narrow Band UVB Light Therapy Compared to Ritlecitinib Alone in Adults with Vitiligo

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Sponsor:Centre Hospitalier Universitaire De Nice

Contact Research Centre

Non-small cell lung cancer

Recruiting

Study of zoldonrasib with daraxonrasib, pembrolizumab and chemotherapy in patients with RAS G12D-mutant non-small cell lung cancer

Registered drugNo placebo

Study of zoldonrasib with daraxonrasib, pembrolizumab and chemotherapy in patients with RAS G12D-mutant non-small cell lung cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Revolution Medicines Inc.

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Bordeaux

What the registry says about research in the country

01 Autoimmune & Inflammatory Conditions

Innovative research focusing on psoriatic arthritis and hidradenitis suppurativa, evaluating new therapeutic combinations and treatment strategies. Studies explore the effectiveness of targeted therapies and novel approaches like fecal microbiota transplantation.

Psoriatic Arthritis Treatment
Inflammatory Skin Conditions
Myasthenia Gravis Management

Clinical trials aim to improve patient outcomes through combination therapies and innovative treatment approaches.

02 Oncology Research

Comprehensive studies investigating treatments for various cancers, including head and neck squamous cell carcinoma, endometrial cancer, and bladder cancer. Research focuses on immunotherapy combinations and targeted treatments.

Advanced Cancer Therapies
Immunotherapy Approaches
Targeted Treatment Strategies

Trials evaluate novel drug combinations and therapeutic approaches for better cancer treatment outcomes.

03 Transplant Medicine

Ground-breaking research in kidney transplantation, focusing on preventing rejection and improving long-term outcomes. Studies evaluate new immunosuppressive strategies and antibody-mediated rejection treatments.

Transplant Rejection Prevention
Immunosuppressive Therapies
Long-term Outcome Studies

Research aims to enhance transplant success rates and patient quality of life.

04 Neurological & Mental Health

Studies examining multiple sclerosis, narcolepsy, and major depressive disorder. Research investigates neuroinflammation patterns and innovative treatment approaches.

Brain Inflammation Studies
Sleep Disorders
Depression Treatment

Trials focus on understanding disease mechanisms and developing targeted therapies.

Back to France All countries